|
Novo Nordisk Strikes $2 Billion Deal for Potential Rival to Lilly’s Triple Agonist Drug
|
Written by: J. Smith |
Hits: 412
|
|
Novo Nordisk Expands $499 Wegovy® Offer to Retail Pharmacies
|
Written by: J. Smith |
Hits: 422
|
|
Dexcom Receives FDA Warning Letter Over Manufacturing Issues
|
Written by: J. Smith |
Hits: 741
|
|
Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations in REDEFINE 2 Trial
|
Written by: J. Smith |
Hits: 465
|
|
Novo Nordisk Launches $499 Cash Program for Wegovy, Matching Eli Lilly’s Zepbound Pricing
|
Written by: J. Smith |
Hits: 477
|
|
Lilly Prepares for High Demand With $550M Stockpile of Oral GLP-1
|
Written by: J. Smith |
Hits: 372
|
|
Dexcom G7 Supply Disruptions
|
Written by: J. Smith |
Hits: 931
|
|
Tandem Diabetes Care Secures FDA Clearance for Control-IQ+ in Type 2 Diabetes
|
Written by: J. Smith |
Hits: 697
|
|
Compounders Sue FDA Over Semaglutide Shortage Decision
|
Written by: J. Smith |
Hits: 593
|
|
Lilly Expands Zepbound Vial Options, Lowers Prices for Self-Pay Patients
|
Written by: J. Smith |
Hits: 671
|
